TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances
Article excerpt
Highlighted: the sentence this signal was extracted from
Bio-Techne Corporation TECH reported adjusted earnings per share (EPS) of 44 cents for the first quarter of fiscal 2027, up 4.8% year over year. The figure surpassed the Zacks Consensus Estimate by 10%. The quarter's adjustments excluded amortization of intangible assets, acquisition-related expenses, stock-based compensation, restructuring costs and certain litigation charges, among others. GAAP EPS was 18 cents compared with 24 cents in the prior-year quarter. Net sales totaled $299.7 million, up 5% year over year on a reported basis and 7% on an organic basis. The figure surpassed the Zacks Consensus Estimate by 2.3%. Foreign currency had an immaterial impact, while a business held for sale had an unfavorable impact of 2%. Consumables revenues increased 2.4% year over year to $237.3 million, while instrument revenues rose 16.8% to $25.5 million. Services revenues declined 18.3% to $22.5 million. Royalty revenues surged to $14.5 million from $5.6 million in the year-ago period. Within Protein Sciences, Bio-Techne recorded revenues of $219.7 million, up 9% year over year from $202.2 million. Organic revenues also increased 9%, while foreign currency had an immaterial impact. The segment's operating margin contracted 50 basis points (bps) to 37.9% from 38.4% in the prior-year quarter. Segment operating income increased to $83.2 million from $77.7 million a year ago...
Keep reading with a free account
The rest of this article, and every signal for Bio-Techne, is in your free account.
